Naftali Kaminski, MD
Cards
Research
About
Contact/Administration
Research
About
Contact/Administration
Research
Publications Overview
- 577 Publications
- 39,940 Citations
- 117 Yale Co-Authors
The Kaminski Lab
Publications Overview
- 577 Publications
- 39,940 Citations
- 117 Yale Co-Authors
The Kaminski Lab
Publications Overview
- 577 Publications
- 39,940 Citations
- 117 Yale Co-Authors
The Kaminski Lab
Titles
Boehringer Ingelheim Pharmaceuticals, Inc. Professor of Medicine (Pulmonary)
Section Chief, Pulmonary, Critical Care & Sleep Medicine
Appointments
Education
Hebrew University (1989)
Hebrew University (1985)
Titles
Boehringer Ingelheim Pharmaceuticals, Inc. Professor of Medicine (Pulmonary)
Section Chief, Pulmonary, Critical Care & Sleep Medicine
Appointments
Education
Hebrew University (1989)
Hebrew University (1985)
Titles
Boehringer Ingelheim Pharmaceuticals, Inc. Professor of Medicine (Pulmonary)
Section Chief, Pulmonary, Critical Care & Sleep Medicine
Appointments
Education
Hebrew University (1989)
Hebrew University (1985)
Contact Info
Pulmonary, Critical Care & Sleep Medicine
300 Cedar Street, TAC-441 South, PO Box 208057
New Haven, CT 06520-8057
United States
Administrative Support
Publications Overview
- 577 Publications
- 39,940 Citations
- 117 Yale Co-Authors
The Kaminski Lab
Publications Overview
- 577 Publications
- 39,940 Citations
- 117 Yale Co-Authors
The Kaminski Lab
Publications Overview
- 577 Publications
- 39,940 Citations
- 117 Yale Co-Authors
The Kaminski Lab
Titles
Boehringer Ingelheim Pharmaceuticals, Inc. Professor of Medicine (Pulmonary)
Section Chief, Pulmonary, Critical Care & Sleep Medicine
Appointments
Education
Hebrew University (1989)
Hebrew University (1985)
Titles
Boehringer Ingelheim Pharmaceuticals, Inc. Professor of Medicine (Pulmonary)
Section Chief, Pulmonary, Critical Care & Sleep Medicine
Appointments
Education
Hebrew University (1989)
Hebrew University (1985)
Titles
Boehringer Ingelheim Pharmaceuticals, Inc. Professor of Medicine (Pulmonary)
Section Chief, Pulmonary, Critical Care & Sleep Medicine
Appointments
Education
Hebrew University (1989)
Hebrew University (1985)
Contact Info
Pulmonary, Critical Care & Sleep Medicine
300 Cedar Street, TAC-441 South, PO Box 208057
New Haven, CT 06520-8057
United States
Administrative Support
Publications Overview
- 577 Publications
- 39,940 Citations
- 117 Yale Co-Authors
The Kaminski Lab
Publications Overview
- 577 Publications
- 39,940 Citations
- 117 Yale Co-Authors
The Kaminski Lab
Publications Overview
- 577 Publications
- 39,940 Citations
- 117 Yale Co-Authors
The Kaminski Lab
About
Titles
Boehringer Ingelheim Pharmaceuticals, Inc. Professor of Medicine (Pulmonary)
Section Chief, Pulmonary, Critical Care & Sleep Medicine
Biography
Dr. Naftali Kaminski is, as of July 1st, 2013, the Boehringer-Ingelheim Endowed Professor of Internal Medicine and Chief of Pulmonary, Critical Care and Sleep Medicine, at Yale School of Medicine. Before that he was a tenured professor of Medicine, Pathology, Computational Biology and Human Genetics, and the Dorothy P. and Richard P. Simmons Endowed Chair for Pulmonary Research at the University of Pittsburgh. Dr. Kaminski was the director of the Dorothy P. and Richard P. Simmons Center for Interstitial Lung Disease and the Lung, Blood and Vascular Center for Genomic Medicine at the division of Pulmonary, Allergy and Critical Care Medicine in University of Pittsburgh. Dr Kaminski received his medical degree from the Hebrew University - Hadassah Medical School in Jerusalem, Israel, and completed a residency in Internal Medicine at Hadassah Mount-Scopus University Hospital in Jerusalem, and a fellowship in pulmonary medicine at Sheba Medical Center in Tel-Hashomer, Israel. Dr Kaminski received his basic science training in Dean Sheppard's laboratory at the Lung Biology Center at UCSF and in functional genomics and microarray technology at the Functional Genomics laboratory at Roche Bioscience, Palo-Alto. After his fellowship in 2000, Dr. Kaminski was appointed head of Functional Genomics at Sheba Medical Center in Israel, before being recruited to head the Simmons Center at the University of Pittsburgh in 2002.
Dr. Kaminski's main research interests involve applying genomic approaches to elucidate basic mechanisms and improve diagnosis and treatment of Idiopathic Pulmonary Fibrosis (IPF), a chronic mostly lethal and currently untreatable scarring lung disease and other chronic lung diseases such Chronic Obstructive Pulmonary Disease (COPD), severe asthma and sarcoidosis. His group pioneered the application of high throughput genome scale transcript profiling in advanced lung disease. Among his key scientific achievements are: The discovery of novel molecules with significant active roles in pulmonary fibrosis, including matrix metalloproteases (MMP7, MMP19) and phosphatases (SHP2, MKP5) , demonstrating that microRNAs, a family of small non-coding RNAs, are differentially expressed in IPF, and that some of them (let-7, mir-29, mir-33) are mechanistically involved in lung fibrosis, and the discovery that the outcome of patients with IPF can be predicted based on the expression of peripheral blood proteins and genes, a finding with practical implication because of the need for risk stratification and transplant prioritization. More recently Dr. Kaminski's team identified a potential antifibrotic role for thyroid hormone signaling, a novel discovery with significant therapeutic implications, and performed single cell RNA sequencing on >300,000 cells obtained from patients with advanced lung disease and created an online freely available data dissemination tool (www.IPFCellAtlas.com). Dr. Kaminski has a strong interest in integrating high throughput ‘omics’ data, such as genome scale DNA variants, coding and non-coding RNAs, microbiome and metabolome information with clinical information to generate systems biology models of lung diseases and to develop precision medicine approaches that are significantly more precise, predictive and patient-centered than anything that is currently available.
Since completing his clinical training, Dr. Kaminski authored more than 340 research papers (including in Nature Medicine, NEJM, Nature Genetics, Nature Communications, PNAS, Science Advances, Science Translational Medicine, Circulation, Lancet Respiratory Medicine, ARCCM and ERJ among others) review articles and book chapters and has given numerous invited talks at national and international conferences, review articles and book chapters and has given numerous invited talks at national and International conferences. Since he finished his fellowship in 2000, Dr. Kaminski has been consistently funded by NIH and is the PI of multiple NIH grants. Dr. Kaminski was a recipient of the Marvin I. Schwarz Award for contributions to patient care and research in pulmonary fibrosis from the Coalition for Pulmonary Fibrosis in 2010 and the University of Pittsburgh Innovator Award in 2012. In 2013, Dr. Kaminski received the American Thoracic Society Recognition of Scientific Achievements award, as well the Helmholtz Institute International Fellow. In 2015 he was elected to the Association of American Physicians. In 2016 he was elected as Fellow of the European Respiratory Society (ERS), and won the European Respiratory Society Gold medal for Interstitial Lung Disease. In 2018, Dr. Kaminski received the Andy Tager Excellence in Mentorship Award from the Respiratory Cell and Molecular Biology Assembly of the American Thoracic Society and was elected fellow of the American Thoracic Society and received the Yale Blavatnik Innovation Award. In 2022 Kaminski received the American Thoracic Society Amberson Lecture award. Dr. Kaminski is active on the ATS and was the editor of “Gene Express”, a column on genomics in the initial days of the ATS Website, a member and chair of the Program Committee of the Assembly on Respiratory Cell and Molecular Biology of the ATS, and member of the ATS Research Advocacy Committee, and Chair of the Assembly on Respiratory, Cell, and Molecular Biology at the American Thoracic Society. He was an associate editor of the American Journal of Respiratory and Critical care Medicine, a member of multiple editorial boards and recently the Deputy Editor of Thorax, BMJ. Dr. Kaminski served as the President of the Association of Pulmonary, Critical Care and Sleep Division Directors in 2019.
Dr. Kaminski is passionate about training physician-scientists for the challenges of 21st century medicine, and especially in the vocabulary, skills and technology of the new fields of genomics, bioinformatics, computational and system biology and their application to understanding the basic mechanisms that govern lung health and disease as well as to designed personalized medicine approaches and has mentored multiple MD and PhD scientists, of them many have productive and well funded independent career. He has most recently recognized for his commitment to mentoring with the American Thoracic Society Andy Tager excellence in mentoring award.
Follow Dr. Kaminski on Twitter @kaminskimed
Follow Dr. Kaminski on mastodon @kaminskimed@med-mastodon.com
<a rel="me" href="https://med-mastodon.com/@Kaminskimed">Mastodon</a>
Appointments
Pulmonary, Critical Care & Sleep Medicine
Section ChiefDualPulmonary, Critical Care & Sleep Medicine
ProfessorPrimaryEnvironmental Health Sciences
ProfessorSecondaryPharmacology
ProfessorSecondary
Other Departments & Organizations
- Center for Biomedical Data Science
- Center for RNA Science and Medicine
- Computational Biology and Biomedical Informatics
- Environmental Health Sciences
- Internal Medicine
- Interstitial Lung Disease (ILD) Program
- Kaminski Lab
- Molecular Medicine, Pharmacology, and Physiology
- Pharmacology
- Pulmonary, Critical Care & Sleep Medicine
- The Center for Precision Pulmonary Medicine (P2MED)
- Yale Combined Program in the Biological and Biomedical Sciences (BBS)
- Yale Fibrosis Program
- Yale Medicine
- Yale Stem Cell Center
Education & Training
- MD
- Hebrew University (1989)
- BM
- Hebrew University (1985)
Research
Overview
Dr. Kaminski’s team main ambition is to uncover the mechanisms, and thus have a significant impact on the management of advanced lung diseases with a specific focus on IPF, a chronic progressive interstitial lung disease that is currently incurable. To study these mechanisms Dr. Kaminski’s team applies systems biology approaches that incorporate a combination of traditional molecular biology methods, high-throughput genomic technologies such as transcript level profiling (single cell RNA sequencing and epigenomic profiling ) , genome scale analyses of gene variants, advanced bioinformatics approaches and targeted proteomic approaches. These studies have led to shifts in the perception of pulmonary fibrosis, the realization that aberrant activation of developmental pathways is at the core of lung fibrosis, the discovery of the role of microRNAs in IPF, the identification and validation of novel prognostic biomarkers in the bloodstream, as well many additional insights.
Mechanisms of pulmonary fibrosis and other chronic lung diseases
- Understanding and identifying the genetic and molecular networks that determine the lung phenotype using high throughput high resolution genomic and proteomic technologies.
- Role of miRNA in advanced lung disease (IPF, Emphysema).
- Role of other non-coding RNAs (lincRNAs) in advanced lung disease
- The IPF Cell Atlas (www.IPFCellAtlas.com)
- The Normal Aging Lung Cell Atlas
- The Pulmonary Fibrosis Connectome
- Epigenomics of chronic lung disease.
- Using computational approaches to Integrate clinical, biological, genomic and proteomic data to identify new molecular phenotypes of disease.
New molecular targets in Pulmonary Fibrosis
- The role and regulation of microRNAs (let-7, mir-33, mir-29) in human pulmonary fibrosis and development of microRNA inhibitors and agonist for therapeutic interventions
- The role of large non-coding RNAs in pulmonary fibrosis
- The role of thyroid hormone signaling in epithelial cell protection in fibrosis
- Novel lung resident cell specific therapeutic approaches in pulmonary fibrosis
Biomarker Discovery and Validation in chronic and progressive lung disease
- Approaches to the development of liquid biopsy in human pulmonary fibrosis and other interstitial lung disease
- Peripheral blood protein markers in lung fibrosis
- Genetic predictors of outcome in lung fibrosis
- Peripheral blood gene expression changes and disease progression
Medical Subject Headings (MeSH)
ORCID
0000-0001-5917-4601- View Lab Website
The Kaminski Lab
Research at a Glance
Yale Co-Authors
Publications Timeline
Research Interests
Taylor Adams
Jonas Christian Schupp, MD
Farida Ahangari, MD
Xiting Yan, PhD
Erica Herzog, MD, PhD
Maor Sauler, MD
Publications
Featured Publications
A lung targeted miR-29 mimic as a therapy for pulmonary fibrosis
Chioccioli M, Roy S, Newell R, Pestano L, Dickinson B, Rigby K, Herazo-Maya J, Jenkins G, Ian S, Saini G, Johnson SR, Braybrooke R, Yu G, Sauler M, Ahangari F, Ding S, DeIuliis J, Aurelien N, Montgomery RL, Kaminski N. A lung targeted miR-29 mimic as a therapy for pulmonary fibrosis. EBioMedicine 2022, 85: 104304. PMID: 36265417, PMCID: PMC9587275, DOI: 10.1016/j.ebiom.2022.104304.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsIdiopathic pulmonary fibrosisNon-human primatesPulmonary fibrosisAnimal modelsPro-fibrotic genesAnti-fibrotic efficacyMiR-29 mimicsHuman peripheral bloodMiR-29b levelsHuman lung fibroblastsIPF patientsIPF diagnosisPeripheral bloodReduced fibrosisAdverse findingsPotential therapyLung slicesTGF-β1Relevant dosesLung fibroblastsNIH-NHLBIFibrosisTherapyCollagen productionProfibrotic gene programAirway basal cells show a dedifferentiated KRT17highPhenotype and promote fibrosis in idiopathic pulmonary fibrosis
Jaeger B, Schupp JC, Plappert L, Terwolbeck O, Artysh N, Kayser G, Engelhard P, Adams TS, Zweigerdt R, Kempf H, Lienenklaus S, Garrels W, Nazarenko I, Jonigk D, Wygrecka M, Klatt D, Schambach A, Kaminski N, Prasse A. Airway basal cells show a dedifferentiated KRT17highPhenotype and promote fibrosis in idiopathic pulmonary fibrosis. Nature Communications 2022, 13: 5637. PMID: 36163190, PMCID: PMC9513076, DOI: 10.1038/s41467-022-33193-0.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsIdiopathic pulmonary fibrosisAirway basal cellsPulmonary fibrosisNovel mouse xenograft modelEffect of saracatinibBasal cellsLimited treatment optionsMouse xenograft modelLung developmental processesConnectivity Map analysisExtracellular matrix depositionIPF lungsBronchial brushSevere fibrosisTreatment optionsBronchial brushingsNRG miceHealthy volunteersXenograft modelCyst-like structuresProfibrotic changesAlveolar compartmentFatal diseaseFibrosisPotent Src inhibitorIntegrated Single-Cell Atlas of Endothelial Cells of the Human Lung
Schupp JC, Adams TS, Cosme C, Raredon MSB, Yuan Y, Omote N, Poli S, Chioccioli M, Rose KA, Manning EP, Sauler M, DeIuliis G, Ahangari F, Neumark N, Habermann AC, Gutierrez AJ, Bui LT, Lafyatis R, Pierce RW, Meyer KB, Nawijn MC, Teichmann SA, Banovich NE, Kropski JA, Niklason LE, Pe’er D, Yan X, Homer RJ, Rosas IO, Kaminski N. Integrated Single-Cell Atlas of Endothelial Cells of the Human Lung. Circulation 2021, 144: 286-302. PMID: 34030460, PMCID: PMC8300155, DOI: 10.1161/circulationaha.120.052318.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsDifferential expression analysisPrimary lung endothelial cellsLung endothelial cellsCell typesMarker genesExpression analysisSingle-cell RNA sequencing dataCross-species analysisVenous endothelial cellsEndothelial marker genesSingle-cell atlasMarker gene setsRNA sequencing dataEndothelial cellsSubsequent differential expression analysisDifferent lung cell typesResident cell typesLung cell typesCellular diversityEndothelial cell typesCapillary endothelial cellsHuman lung endothelial cellsPhenotypic diversityEndothelial diversityIndistinguishable populationsThyroid hormone inhibits lung fibrosis in mice by improving epithelial mitochondrial function
Yu G, Tzouvelekis A, Wang R, Herazo-Maya JD, Ibarra GH, Srivastava A, de Castro JPW, DeIuliis G, Ahangari F, Woolard T, Aurelien N, Arrojo e Drigo R, Gan Y, Graham M, Liu X, Homer RJ, Scanlan TS, Mannam P, Lee PJ, Herzog EL, Bianco AC, Kaminski N. Thyroid hormone inhibits lung fibrosis in mice by improving epithelial mitochondrial function. Nature Medicine 2017, 24: 39-49. PMID: 29200204, PMCID: PMC5760280, DOI: 10.1038/nm.4447.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsmicroRNA-33 deficiency in macrophages enhances autophagy, improves mitochondrial homeostasis, and protects against lung fibrosis
Ahangari F, Price N, Malik S, Chioccioli M, Bärnthaler T, Adams T, Kim J, Pradeep S, Ding S, Cosme C, Rose K, McDonough J, Aurelien N, Ibarra G, Omote N, Schupp J, DeIuliis G, Nunez J, Sharma L, Ryu C, Dela Cruz C, Liu X, Prasse A, Rosas I, Bahal R, Fernandez-Hernando C, Kaminski N. microRNA-33 deficiency in macrophages enhances autophagy, improves mitochondrial homeostasis, and protects against lung fibrosis. JCI Insight 2023, 8: e158100. PMID: 36626225, PMCID: PMC9977502, DOI: 10.1172/jci.insight.158100.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsIdiopathic pulmonary fibrosisPulmonary fibrosisMiR-33MiR-33 levelsSpecific genetic ablationBronchoalveolar lavage cellsNovel therapeutic approachesMitochondrial homeostasisFatty acid metabolismMacrophages protectsBleomycin injuryLavage cellsLung fibrosisHealthy controlsInflammatory responseTherapeutic approachesImmunometabolic responsesCholesterol effluxFibrosisFatal diseasePharmacological inhibitionSterol regulatory element-binding protein (SREBP) genesGenetic ablationMacrophagesEx vivo mouse
2024
SDePER: a hybrid machine learning and regression method for cell-type deconvolution of spatial barcoding-based transcriptomic data
Liu Y, Li N, Qi J, Xu G, Zhao J, Wang N, Huang X, Jiang W, Wei H, Justet A, Adams T, Homer R, Amei A, Rosas I, Kaminski N, Wang Z, Yan X. SDePER: a hybrid machine learning and regression method for cell-type deconvolution of spatial barcoding-based transcriptomic data. Genome Biology 2024, 25: 271. PMID: 39402626, PMCID: PMC11475911, DOI: 10.1186/s13059-024-03416-2.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsINTERACTIONS BETWEEN MITOCHONDRIAL DNA AND TOLL-LIKE RECEPTOR 9 MEDIATES PULMONARY FIBROSIS
LEE C, TRUJILLO G, REGUEIRO-REN A, LIU C, HU B, SUN Y, KHOURY J, KHOURY J, AHANGARI F, ISHIKAWA G, WALIA A, PIVARNIK T, YU S, WOO S, FIORINI V, MCGOVERN J, AL JUMAILY K, SUN H, PENG X, ANTIN-OZERKIS D, SAULER M, KAMINSKI N, HERZOG E. INTERACTIONS BETWEEN MITOCHONDRIAL DNA AND TOLL-LIKE RECEPTOR 9 MEDIATES PULMONARY FIBROSIS. CHEST Journal 2024, 166: a3384-a3386. DOI: 10.1016/j.chest.2024.06.2020.Peer-Reviewed Original ResearchToll-like Receptor 9 Inhibition Mitigates Fibroproliferative Responses in Translational Models of Pulmonary Fibrosis.
Trujillo G, Regueiro-Ren A, Liu C, Hu B, Sun Y, Ahangari F, Fiorini V, Ishikawa G, Al Jumaily K, Khoury J, McGovern J, Lee C, Peng X, Pivarnik T, Sun H, Walia A, Woo S, Yu S, Antin-Ozerkis D, Sauler M, Kaminski N, Herzog E, Ryu C. Toll-like Receptor 9 Inhibition Mitigates Fibroproliferative Responses in Translational Models of Pulmonary Fibrosis. American Journal Of Respiratory And Critical Care Medicine 2024 PMID: 39189851, DOI: 10.1164/rccm.202401-0065oc.Peer-Reviewed Original ResearchAltmetricConceptsToll-like receptor 9Model of pulmonary fibrosisIdiopathic pulmonary fibrosisPulmonary fibrosisFibroproliferative responseLung diseaseIdiopathic pulmonary fibrosis cohortsExpression of toll-like receptor 9Toll-like receptor 9 activationTransplant-free survivalExpression of MCP-1Cohort of patientsSlow clinical progressionFibrotic lung diseaseAccelerated disease courseFatal lung diseaseIP-10Pharmacodynamic endpointsPreclinical modelsDisease courseClinical progressionPlasma mtDNAMCP-1Receptor 9Mouse modelSpatial transcriptomic validation of a biomimetic model of fibrosis enables re-evaluation of a therapeutic antibody targeting LOXL2
Bell J, Davies E, Brereton C, Vukmirovic M, Roberts J, Lunn K, Wickens L, Conforti F, Ridley R, Ceccato J, Sayer L, Johnston D, Vallejo A, Alzetani A, Jogai S, Marshall B, Fabre A, Richeldi L, Monk P, Skipp P, Kaminski N, Offer E, Wang Y, Davies D, Jones M. Spatial transcriptomic validation of a biomimetic model of fibrosis enables re-evaluation of a therapeutic antibody targeting LOXL2. Cell Reports Medicine 2024, 5: 101695. PMID: 39173635, PMCID: PMC11524965, DOI: 10.1016/j.xcrm.2024.101695.Peer-Reviewed Original ResearchAltmetricSingle-Cell Profiling Reveals Immune Aberrations in Progressive Idiopathic Pulmonary Fibrosis.
Unterman A, Zhao A, Neumark N, Schupp J, Ahangari F, Cosme C, Sharma P, Flint J, Stein Y, Ryu C, Ishikawa G, Sumida T, Gomez J, Herazo-Maya J, Dela Cruz C, Herzog E, Kaminski N. Single-Cell Profiling Reveals Immune Aberrations in Progressive Idiopathic Pulmonary Fibrosis. American Journal Of Respiratory And Critical Care Medicine 2024, 210: 484-496. PMID: 38717443, PMCID: PMC11351796, DOI: 10.1164/rccm.202306-0979oc.Peer-Reviewed Original ResearchCitationsAltmetricConceptsStable idiopathic pulmonary fibrosisIdiopathic pulmonary fibrosisPeripheral blood mononuclear cellsProgressive idiopathic pulmonary fibrosisPeripheral immune systemT cellsPulmonary fibrosisCohort of IPF patientsAssociated with decreased survivalIdiopathic pulmonary fibrosis patientsPeripheral blood mononuclear cell samplesPeripheral blood cell populationsImmune systemFraction of TregsRegulatory T cellsBlood mononuclear cellsBlood cell populationsFlow cytometry analysisImmune aberrationsIPF patientsTregsMononuclear cellsSingle-cell RNA sequencingLung homogenatesMonocyte chemoattractant
Academic Achievements & Community Involvement
activity New England Journal of Medicine
Journal ServiceReviewerDetails2002 - Presentactivity Nature Medicine
Journal ServiceReviewerDetails2002 - Presentactivity Cell
Journal ServiceReviewerDetails2002 - Presentactivity Public Library of Science (PLoS) Medicine
Journal ServiceReviewerDetails2002 - Presentactivity Proceedings of the National Academy of Sciences (PNAS)
Journal ServiceReviewerDetails2002 - Present
Clinical Care
Are You a Patient?
Please visit the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileRelated Yale Medicine Content
1 Condition Fact Sheet3 Clinical Departments1 News ArticleSee All Related Content on Yale Medicine
Overview
Naftali Kaminski, MD, chief of Yale Medicine Pulmonary, Critical Care and Sleep Medicine, is a leader in improving the understanding and treatment of chronic lung diseases. He has a particular interest in idiopathic pulmonary fibrosis, a disease characterized by progressive scarring of the lungs, and in chronic obstructive pulmonary disease and asthma.
Dr. Kaminski leads the Kaminski Lab at Yale School of Medicine, where researchers apply cutting-edge technologies that measure changes in the sequence, expression or regulation of all the genes in the human genome in efforts to learn more about the roles of genome networks and biomarkers in chronic lung disease.
“Pulmonary fibrosis was an understudied and poorly understood disease, with high mortality and morbidity,” says Dr. Kaminiski, who is a professor of medicine (pulmonary) at Yale School of Medicine “I thought that by shifting the focus to human
relevant pathways and mechanisms we can have an impact, and we have.”
Clinical Specialties
Fact Sheets
Interstitial Lung Disease (ILD)
Learn More on Yale Medicine
Yale Medicine News
News & Links
Media
- Dr. Kaminski Receiving the Helmholtz International Award from Dr. Eickelberg in Munich, June 2013
News
- August 21, 2024
Unique Immune Profile Identified in Fibrotic Hypersensitivity Pneumonitis
- July 01, 2024
Dr. Carolyn L. Rochester received the American Thoracic Society (ATS) Assembly on Pulmonary Rehabilitation Lifetime Achievement Award
- May 30, 2024
Single-Cell Profiling Reveals Insights About Immunity in Idiopathic Pulmonary Fibrosis
- May 13, 2024
Five Reasons To See a Pulmonologist
Related Links
- Dr. Kaminski answers to the question "What Excites you Most about the Future?"
- Dr. Kaminski is joining Yale faculty as Chief of Pulmonary, Critical Care and Sleep Medicine
- IPF Awareness at Yale PCCSM 2014
- Jerusalem Post: Israeli becomes top world expert on lung disease
- Role of Biomarkers in Diagnosis and Treatment of IPF
- Dr. Kaminski speaking about advocacy for ending sexual harassment and gender inequality
- Dr. Kaminski speaking about Cell-based Precision Medicine Approaches to PF in the PF Summit 2020
- Introduction of the Kaminski Lab to computational Students
- Dr. Kaminski speaks about the role of men in fighting gender inequality and sexual harassment at the Branford Forum
- Dr. Kaminski's Amberson Award Talk
Get In Touch
Contacts
Pulmonary, Critical Care & Sleep Medicine
300 Cedar Street, TAC-441 South, PO Box 208057
New Haven, CT 06520-8057
United States
Administrative Support
Locations
The Anlyan Center
Academic Office
300 Cedar Street, Ste S441D
New Haven, CT 06519
Appointments
203.737.4612
Events
Yale Only Naftali Kaminski, MD